Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Oncternal Therapeutics Inc is a biotechnology business based in the US. Oncternal Therapeutics shares (ONCT) are listed on the NASDAQ and all prices are listed in US Dollars. Oncternal Therapeutics employs 12 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.68|
|52-week range||$1.49 - $10.56|
|50-day moving average||$4.10|
|200-day moving average||$4.83|
|Wall St. target price||$15.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-2.90%|
|1 month (2021-09-24)||-16.36%|
|3 months (2021-07-23)||-6.84%|
|6 months (2021-04-23)||-42.05%|
|1 year (2020-10-23)||120.36%|
|2 years (2019-10-24)||-33.27%|
|3 years (2018-10-24)||131.45%|
|5 years (2016-10-24)||327.91%|
|Revenue TTM||$3.8 million|
|Gross profit TTM||$-9,169,000|
|Return on assets TTM||-20.52%|
|Return on equity TTM||-36.72%|
|Market capitalisation||$181.7 million|
TTM: trailing 12 months
There are currently 1.7 million Oncternal Therapeutics shares held short by investors – that's known as Oncternal Therapeutics's "short interest". This figure is 11.2% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Oncternal Therapeutics shares can be evaluated.
Oncternal Therapeutics's "short interest ratio" (SIR) is the quantity of Oncternal Therapeutics shares currently shorted divided by the average quantity of Oncternal Therapeutics shares traded daily (recently around 505426.70623145). Oncternal Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Oncternal Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.
However Oncternal Therapeutics's short interest can also be evaluated against the total number of Oncternal Therapeutics shares, or, against the total number of tradable Oncternal Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncternal Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Oncternal Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0353% of the tradable shares (for every 100,000 tradable Oncternal Therapeutics shares, roughly 35 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncternal Therapeutics.
Find out more about how you can short Oncternal Therapeutics stock.
We're not expecting Oncternal Therapeutics to pay a dividend over the next 12 months.
Oncternal Therapeutics's shares were split on a 1:7 basis on 9 June 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oncternal Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Oncternal Therapeutics shares which in turn could have impacted Oncternal Therapeutics's share price.
Over the last 12 months, Oncternal Therapeutics's shares have ranged in value from as little as $1.49 up to $10.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncternal Therapeutics's is 1.5459. This would suggest that Oncternal Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.